EU Startup News’ Post

Innovation is a transformative force, constantly pushing the boundaries of what’s possible in the world of biotechnological discoveries. Just imagine - expanding immunotherapies to cancer patients, harnessing the power of the 'junk DNA', targeting the molecular machines underlying human disease, making B cells as medicines, progressing monoclonal antibody TREM2... this list goes on and on! Immerse yourself in this fascinating world, and meet Cambridge’s brightest minds and their revolutionary biotech startups, woven together in our latest article: "https://lnkd.in/grnKv4Q4" Featuring: NextPoint Therapeutics, Inc., founded by Gordon Freeman and Xingxing Zang ROME Therapeutics, founded by Rosana Kapeller MOMA Therapeutics, founded by Dorothee Kern, Eva Nogales, Johannes Walter, Timur Yusufzai Be Biopharma, founded by Aleks Radovic-Moreno, David Rawlings, David Steinberg, Lea Hachigian Vigil Neuroscience Theonys, founded by Nick Davis Clade Therapeutics, founded by Chad Cowan, Jim Glasheen, Leandro Vetcher Faze Medicines, founded by J. Paul Taylor, Mike Rosen, Ron Vale, Roy Parker Totus Medicines, founded by Neil Dhawan Transition Bio, Inc., founded by David Weitz, Peter St George-Hyslop, Sarah Teichmann, Tuomas Knowles Catamaran Bio, founded by Branden S. Moriarity, Kevin Pojasek Join us in applauding the efforts of these trailblazing biotech startups in revolutionising the biological technology sector, and pour into this article that captures their inspiring journey! #biotech #innovation #Cambridgestartups #startups #biotechnology #healthcare #pharma #cancerresearch #Genomics #drugdiscovery #healthtech

🥇 We are incredibly honored that Insilico Medicine was named the #1 biotech company in Fast Company's 2024 World's Most Innovative Companies list. They write: “In 2023, it was hard to escape the hype around AI, regardless of the industry. In biotechnology, it seemed to hit a fever pitch...While it is much too soon to evaluate the variety of approaches, or to judge their ultimate success, there are a few companies that have made real progress. Insilico Medicine is arguably the furthest along, dosing the first patient in its Phase 2 trial of a lung-disease treatment identified and designed using its generative-AI platform..." It has been a remarkable year. A few highlights: ◾ publishing the story of our lead drug in Nature Biotechnology; ◾ supporting a new treatment for ALS designed with our platform; ◾ developing drugs for “undruggable” cancer targets in partnership with the University of Toronto; ◾ bringing a new AI-designed treatment for IBD to clinical trials; ◾ nominating a potentially best-in-class preclinical candidate for ovarian and breast cancer; ◾ publishing findings on a new, potent, AI-discovered target for breast and gynecological cancer; ◾ and signing significant licensing deals on our AI-designed anti-cancer assets with the MENARINI Group and Exelixis. *Links in comments. #FCMostInnovative #AI #genai #biotech #techbio #awards #drugdiscovery #innovation

Which will be the future of oncology? Yesterday at #VivaTech, while searching for biotechnological innovations, I found the Gustave Roussy tech transfer booth. Please, take a look at three of the presented proposals: Orakl Oncology Integrating AI-powered analysis of Patient-Derived Organoids for better, faster, and cost-effective treatments. It will involve the development of an automated lab system to license it to other healthcare centers around the globe. Cure51 There is a 3% of exceptional patients who survive the most lethal cancers. By characterizing their exceptional traits, they plan to find out which mechanisms and biomarkers are related to this "miracle." A simple but fascinating strategy that can lead to several business plans and is definitely a startup to keep an eye on. Elikya Therapeutics Focusing on the improvement of Antibody Drug Conjugates (ADCs) in oncology based on its own toxic payloads. Designed to fight against cancer cells and the tumoral microenvironment with a differentiated mechanism of action. A big thank you to the presenters, and I hope to see more technological approaches to biology in the future. Looking forward to connecting with fellow attendees. Feel free to reach out if you want to discuss AI and biotechnology integration further! #OncologyResearch #Biotechnology #VivaTech #CancerResearch #BiotechInnovations #HealthTech #Startups #HealthcareInnovation

Exciting news! We have a brand-new feature on some of the promising biotechnology startups making waves in Cambridge. They are tackling everything from untreatable diseases to cutting-edge cell therapies. You won’t want to miss this! You can read all about them here: https://lnkd.in/gCA4g4Kn Featuring: NextPoint Therapeutics, Inc., founded by Gordon Freeman and Xingxing Zang, they are developing groundbreaking immunotherapies to extend benefits to cancer patients. ROME Therapeutics, led by Rosana Kapeller, is on a mission to create innovative treatments for cancer and autoimmune diseases. MOMA Therapeutics, by the team of Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai, are exploring precision medicines by targeting molecular machines causing diseases. Be Biopharma, backed by Aleks Radovic-Moreno, David Rawlings, David Steinberg, and Lea Hachigian, works on developing a class of B cells as medicines. Vigil Neuroscience, striving to advance treatments for neurogenerative diseases. Theonys, sparked into existence by Nick Davis, seeks to treat complex diseases like cancer by using tRNA. Clade Therapeutics, co-founded by Chad Cowan, Jim Glasheen, and Leandro Vetcher, focuses on providing scalable, off-the-shelf, next-gen stem cell-based medicines. Faze Medicines, the brainchild of J. Paul Taylor, Mike Rosen, Ron Vale, and Roy Parker, uses proteomics techniques to define condensate interaction networks. Totus Medicines, led by Neil Dhawan, uses revolutionary chemical biology to fight untreatable diseases. Transition Bio, Inc., the work of David Weitz, Peter St George-Hyslop, Sarah Teichmann, and Tuomas Knowles, employs condensate technology for drug discovery and diagnostics. Catamaran Bio, co-created by Branden S. Moriarity, and Kevin Pojasek, pioneers in allogeneic immune cell therapies. Each of these companies and their founders represent the thrilling future of biotechnology. Stay tuned for more! #biotech #startups #innovation #Cambridge #healthcare #lifesciences #therapeutics

🚀 Major Funding Boost for Neurodegenerative Disease Research! 🧠 Forbion-backed Vectory Therapeutics has successfully raised $138 million to advance research into ALS and other neurodegenerative diseases. This significant funding will accelerate the development of innovative therapies, bringing hope to patients and families affected by these challenging conditions. Key Points: Funding Amount: $138 million Focus Areas: Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases Backed By: Forbion, a leading life sciences venture capital firm Impact: This funding will enable Vectory Therapeutics to accelerate the development of groundbreaking treatments and potentially transform the landscape of neurodegenerative disease research. Read more about this exciting development here: https://lnkd.in/gTuTZraD #Biotech #ALSResearch #NeurodegenerativeDiseases #Funding #HealthcareInnovation #VectoryTherapeutics #Forbion #MedicalResearch

🍀 Change is afoot in the biotech world and we're thrilled to spotlight some of the trailblazers shaping its future. Our latest feature uncovers the most innovative biotech engineering companies based in Washington that are revolutionizing the industry. https://lnkd.in/ggxcfMNJ BioViva USA Inc.: Spearheading regenerative medicine, founded by Liz Parrish MBA & Jason Williams. Alpine Immune Sciences, Inc.: Innovating in immune modulation, created by Michael Kornacker, Mitchell Gold M.D., Mitchell H. Gold, Ryan Swanson. Hemeos Specializing in innovative blood and organ transplantation solutions. Vaylenx: Advancing in biocompatible materials for healthcare. Silverback Therapeutics: Focused on targeted therapies, established by Badreddin Edris & Peter Thompson. OncoResponse: Pioneering in cancer immunotherapy, founded by Clifford J. Stocks. Aptevo Therapeutics Inc: Developing novel oncology and hematology therapies, initiated by Marvin L. White. Good Therapeutics, Inc.: Revolutionizing targeted drug delivery, conceived by John Mulligan, Ph.D. MAVUPHARMA, INC.: Leading in the field of non-oncology biotech, started by Michael Gallatin. Proniras Corporation: Innovating in neuroscience and CNS disorders, founded by Christopher Toombs. Taproot Medical Technologies: Specializing in new medical device technologies, established by Shaoyi Jiang. #BiotechEngineering #Innovation #Healthcare #HealthTech #Biotechnology #IndustryLeaders

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Early-stage oncology startup Boundless Bio files for IPO: Boundless Bio has filed to go public as it approaches early safety and efficacy data for its first clinical attempt at a unique take on treating cancer. The five-year-old San Diego startup revealed its plans Wednesday to trade on the Nasdaq as “BOLD.” The move comes as investor sentiment picks up with a flurry of follow-on offerings and renewed interest in crossover rounds. Boundless, one of the many startups in ARCH Venture Partners’ sprawling portfolio, had previously raised about $250 million on the private side, including a $100 million Series C last May, shortly before it brought on ex-EQRx finance chief Jami Rubin to run finances. “If Boundless is successful, we have the potential to create a whole new vertical in cancer therapeutics with drugs that target the root cause of amplification,” Rubin told Endpoints News last July. Boundless would be the third cancer drug developer to go public this year after CG Oncology and ArriVent, both of which upsized their IPOs and traded up on their first day on the Nasdaq. Cardiometabolic gene therapy developer Fractyl Health, CNS biotech Alto Neuroscience, autoimmune CAR-T company Kyverna Therapeutics and preclinical gene editing startup Metagenomi have also gone public this year. The company is honing in on tiny DNA circles floating outside chromosomes, an approach based on work from Stanford researcher Paul Mischel. The wily circles are a culprit of cancer growth and resistance. Patients were dosed in Boundless’ first trial last May. The company anticipates early efficacy data on the oral CHK1 inhibitor, known as BBI-355, this year. The company said earlier Wednesday it will have multiple presentations at the annual meeting of the American Association for Cancer Research next month. The biotech said in the filing it plans to have preliminary data from its second oral candidate, BBI-825, in the second half of 2025. The ribonucleotide reductase inhibitor has potential in settings such as resistance associated with treatment of KRASG12C mutant colorectal cancer, Boundless said last October. #lucidquest #genetherapy #celltherapy

Gene&Cell Therapy >> Early-stage oncology startup Boundless Bio files for IPO: Boundless Bio has filed to go public as it approaches early safety and efficacy data for its first clinical attempt at a unique take on treating cancer. The five-year-old San Diego startup revealed its plans Wednesday to trade on the Nasdaq as “BOLD.” The move comes as investor sentiment picks up with a flurry of follow-on offerings and renewed interest in crossover rounds. Boundless, one of the many startups in ARCH Venture Partners’ sprawling portfolio, had previously raised about $250 million on the private side, including a $100 million Series C last May, shortly before it brought on ex-EQRx finance chief Jami Rubin to run finances. “If Boundless is successful, we have the potential to create a whole new vertical in cancer therapeutics with drugs that target the root cause of amplification,” Rubin told Endpoints News last July. Boundless would be the third cancer drug developer to go public this year after CG Oncology and ArriVent, both of which upsized their IPOs and traded up on their first day on the Nasdaq. Cardiometabolic gene therapy developer Fractyl Health, CNS biotech Alto Neuroscience, autoimmune CAR-T company Kyverna Therapeutics and preclinical gene editing startup Metagenomi have also gone public this year. The company is honing in on tiny DNA circles floating outside chromosomes, an approach based on work from Stanford researcher Paul Mischel. The wily circles are a culprit of cancer growth and resistance. Patients were dosed in Boundless’ first trial last May. The company anticipates early efficacy data on the oral CHK1 inhibitor, known as BBI-355, this year. The company said earlier Wednesday it will have multiple presentations at the annual meeting of the American Association for Cancer Research next month. The biotech said in the filing it plans to have preliminary data from its second oral candidate, BBI-825, in the second half of 2025. The ribonucleotide reductase inhibitor has potential in settings such as resistance associated with treatment of KRASG12C mutant colorectal cancer, Boundless said last October. #lucidquest #genetherapy #celltherapy

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Nvidia's biotech moment; Regeneron launches venture arm; New GLP-1 player enters; Sanofi rejigs cancer pact, vaccine ops; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Next month, we will be partnering with the Financial Times on its US Pharma and Biotech Summit returns to New York. There are options for both in-person and virtual attendance — you can find the speakers and agenda here. Nvidia’s biotech moment Over the last decade, multiple tech giants have tried and failed to get into healthcare. Nvidia, though, appears to be the exception. Is this finally tech’s healthcare moment? Andrew Dunn takes a deep dive into the chipmaker’s plan to dominate biotech’s AI revolution. Regeneron launches venture arm Regeneron is getting into venture investing. The storied drugmaker will commit $100 million per year for five years to Regeneron Ventures, which will invest in biotech startups, devices, tools and “enabling technologies.” The fund will be led by former Regeneron execs. New GLP-1 player enters ARCH-backed startup Metsera officially launched with $290 million to challenge Novo Nordisk and Eli Lilly’s duopoly atop today’s market for obesity drugs. Its lead asset is a GLP-1 agonist now in the clinic in the US, and it plans to test combinations of various drugs, but the rest of the clinical strategy remains closely guarded. Sanofi rejigs cancer pact, vaccine ops Sanofi isn’t done reorganizing its businesses. In addition to trimming its $6.15 billion biobuck pact with California biotech IGM — removing the three targets they had planned in oncology and thus taking $3 billion off the table — it is also overhauling its US commercial operations for its vaccines and will cut an undisclosed number of jobs. WHAT WE’RE WATCHING NEXT WEEK Multiple pharma companies are set to report their Q1 earnings, including Sanofi, Roche, Novartis, AstraZeneca, GSK and more. R&D * Eli Lilly’s weight loss drug Zepbound hit the primary endpoints in two Phase 3 trials for adults with obstructive sleep apnea and obesity, setting the stage for the first potential approval of a drug for the breathing disorder. The company is planning a filing in mid-2024. * Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal * Sage nixes program for Parkinson’s disease after Phase 2 failure * Cerevel notches Phase 3 Parkinson’s win ahead of AbbVie transaction closing * FDA hits Neumora with clinical hold for schizophrenia drug after preclinical data showed convulsions in rabbits * Novartis showcases Ph3 data… #lucidquest #genetherapy #celltherapy

Do you know who is pioneering a revolution in the UK's Healthcare Industry? You won't believe it but it's right here, nestled within the innovative hotbed of Cambridge! But wait, we've done more than just tell you that. We've put together a comprehensive article feature on the phenomenal startups that are enacting this change. Keen to know more? Dive into it here: (https://lnkd.in/dBwZbxRH) Featuring: NextPoint Therapeutics, Inc., leading innovation in immunotherapies, founded by Gordon Freeman and Xingxing Zang. ROME Therapeutics, transforming healthcare with cutting-edge therapies, steered by Rosana Kapeller. Vigil Neuroscience, focusing on advancing revolutionary medications. Clade Therapeutics, pushing the boundaries of stem-cell-based therapies, helmed by Chad Cowan, Jim Glasheen, and Leandro Vetcher. Transition Bio, Inc., applying condensate technology for diagnostics, spearheaded by David Weitz, Peter St George-Hyslop, Sarah Teichmann, and Tuomas Knowles. Catamaran Bio, specialized in allogeneic immune cell therapies, led by Branden S. Moriarity and Kevin Pojasek. AavantiBio, Inc., creating breakthroughs in life sciences led by Barry Byrne and Manuela Corti. Proof Diagnostics, Inc., revolutionising COVID-19 testing, founded by Feng Zhang, Jonathan Gootenberg, Omar Abudayyeh, and Siddharth Shenai. Bicara Therapeutics, bringing cutting-edge therapies to cancer patients. NextRNA Therapeutics, pushing innovative therapeutics, founded by Dominique Verhelle, Julia Novina, Leon Wert-Lamas, and Marc Cohen. Kojin Therapeutics, helmed by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, accelerating innovative therapies for hard-to-treat diseases. Dive into the #healthcare revolution happening right at our doorstep! #startups #innovation #Cambridge #healthtech #biotech #lifesciences #therapeutics